Skip to main content
Premium Trial:

Request an Annual Quote

Cenix Adds Respiratory, Inflammatory Diseases to RNAi-Screening Deal With AstraZeneca


Cenix BioScience announced this week that it has signed multi-year deal to use its RNAi screening technology to discover novel drug targets for respiratory and inflammatory disease for AstraZeneca.

According to Cenix, the deal expands upon the companies' existing research arrangement in oncology, which was signed in 2008 (see GenomeWeb Daily News, 3/19/2008).

Under the new deal, Cenix will complete at least three projects for AstraZeneca that combine "multi-pass genome-scale screens for the discovery of novel [respiratory and inflammatory disease] target candidates with detailed validation analyses … using a number of primary human cell types," the company said.

Cenix will also adapt assays developed by AstraZeneca scientists to optimize their use in high-throughput RNAi studies in 384-well and/or 1,536-well formats.

Financial terms of the deal were not disclosed.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.